Morse, Michael A., Smita K. Nair, Paul J. Mosca, Amy C. Hobeika, Timothy M. Clay, Yuping Deng, David Boczkowski, et al. “Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA.” Cancer Invest 21, no. 3 (June 2003): 341–49. https://doi.org/10.1081/cnv-120018224.
Herbert Kim Lyerly, MD
George Barth Geller Distinguished Professor of Immunology
Campus Mail:
203 Research Drive, Rm 433B, Box 2606, Durham, NC 27710
Phone:
(919) 681-8350
Email:
lyerl001@mc.duke.edu
Education and Training
- M.D., University of California - Los Angeles, 1983
Selected Grants and Awards
- Visualizing tumor heterogeneity in an immune intact and autochthonous mouse model of breast cancer
- Therapeutic targeting of breast cancer and host immune responses at inflection points in the disease trajectory
- Enabling effective anti-tumor immunity from targeted antibodies through dual innate and adaptive immune checkpoint blockade in non-immunogenic cancers
- Duke University Program in Environmental Health
- Viral Oncology Training Grant
- Beyond PD1: An immunotherapeutic strategy to stimulate and enable both T-cell and B-cell responses in immunosuppressive and non-mutated metastatic breast cancer
- Determinants of geographic disparities in mortality and multimorbidity in the U.S.
- Hebei Bio-High Technology Visiting Researcher Training
- R01 Defining the Rules of Breast Cancer Cell Traffic Through Bone
- Detection and Elimination of Oncogenic Signaling Networks in Pre-malignant and Malignant Cells with Magnetic Resonance Imaging
- Developing a HER3 Vaccine to Prevent Resistance to Endocrine Therapy
- Translational Research in Surgical Oncology
- A Molecular Framework for Understanding DCIS
- Establishing the molecular and cellular mechanisms of Lgr5 signaling for controlling cancer stem cell behavior
- UNC - Duke Immunotherapy Training Program
- Transfusion Medicine and Hematology
- Mechanisms of Action and Resistance to PD-1 Immunotherapies in Breast Cancer
- Immunotherapeutic Targeting of a Therapy Resistant Oncogenic HER2 Isoform
- Investigating Adaptive Immune Recognition of Dormant Disseminated Tumor Cells
- Inhibition of Wnt/B-Catenin Signaling in Colorectal Cancer Therapy
- Duke University Program in Environmental Health
- 3D Biology Signatures defined by Nanostring Max System
- Duke-Komen Fundamentals Training for Patient Advocates - AAADV
- A Cancer Rainbow Mouse for Simultaneous Assessment of Multiple Oncogenes
- AAADV Fundamentals
- Advancing Immunology in Dogs with Naturally-occurring Invasive Bladder Cancer, a Relevant Model to Improve Immunotherapy Across Molecular Cancer Subtypes in Humans
- A Simple System for Early Detection of Breast Cancer
- AAADV Scholars
- AAADV Scholars
- AAADV Scholars
- AAADV Workshop
- Cancer Biology Training Grant
- Integrating Population and Basic Science in Cancer Research
- Clinical Oncology Research Career Development Program
- 2015 Accelerating Anticancer Agent Development and Validation Workshop
- A Cancer Rainbow Mouse for the Simultaneous Assessment of Multiple Oncogenes
- Administrative Supplement for Recruitment of New Faculty
- Immunotherapy with High Frequency, CEA Specific
- SPORE in Breast Cancer
- Cancer Center Core Grant Supplement - Accelerating Anticancer Agent Development Workshop
- Cancer Center Core Grant Supplement - Accelerating Anticancer Agent Dev Workshop
- Targeting hCG-beta for Breast Cancer Immunotherapy
- Developing Biomarker-Based Prognostics in Breast Cancer
- Vaccination with Regulatory T Cell Depletion
- Markers of short term breast cancer risk in FNA
- Novel Biomarkers for Aromatase Inhibitor Therapy
- Phase II trial of Cetuximab & Carboplatin in Basal-like Breast Cancer
- Biomarker Studies for Novel Anti-Cancer Agents
- Dendritic Cell Based Immunotherapy
- Immunotherapy using peptide MHC tetramer isolated Tcells
- Dendritic Cell Mobilization and Active Immunotherapy
- Immunologic Correlates of Effective Immunizations for Cancer Vaccines
- Planning a Duke Academic Public Private Partnership Program (AP4) Center
- Phase II Trial of Estradiol Therapy for Advanced Breast Cancer
- Mentored Oriented Research Career Development Award
- Cancer Center Core Grant - CURE Supplment
- Immunotherapy of Prostate Cancer with Tumor Vaccines
- RNA Transfected Dendritic Cells for Cancer Immunotherapy
- Dexasome Based Immunotherapy of Lung Cancer
- Immunotherapy with TRICOM Modified Dendritic Cells
- Cytomation MoFlo High Performance Flow Cytometer
- Dendritic Cell Immunotherapy For Breast Cancer
- Cancer Immunotherapy With Rna Pulsed Dendritic Cells
- Immunotherapy With Peptide Pulsed Dendritic Cells
- Immunotherapy with peptide pulsed dendritic cell
- Viral Control And Immune Reconstitution In Hiv Infection
- Viral Control & Immune Reconstitution In Hiv Infection
- Immunotherapy Of Breast Cance5 With Gene Modified Tumor
- Immunotherapy Of Breast Cancer With Gene Modified Tumor
- Immunotherapy of Breast Cancer with Gene Modified Tumors
- DUMC AIDS Malignancy Program
- Dumc Aids Malignancy Program
- Spore In Breast Cancer
- Spore In Breast Cancer
- Surrogate Markers Of Tumor Specific Immunity
- Preclinical Development Of Rna Decoys
- Adoptive Immunotherapy For Aids Lymphoma
- Cellular Immunity Against Post-Transplant Lymphoma
Selected Publications
Morse, Michael A., Timothy M. Clay, Kirsten Colling, Amy Hobeika, Ken Grabstein, Martin A. Cheever, and H Kim Lyerly. “HER2 dendritic cell vaccines.” Clin Breast Cancer 3 Suppl 4 (February 2003): S164–72. https://doi.org/10.3816/cbc.2003.s.007.
Mosca, Paul J., Amy C. Hobeika, Kirsten Colling, Timothy M. Clay, Elaine K. Thomas, Dania Caron, H Kim Lyerly, and Michael A. Morse. “Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand.” J Leukoc Biol 72, no. 3 (September 2002): 546–53.
Morse, Michael A., David Rizzieri, Timothy T. Stenzel, Amy C. Hobeika, James J. Vredenburgh, Nelson J. Chao, Timothy M. Clay, Paul J. Mosca, and H Kim Lyerly. “Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants.” J Hematother Stem Cell Res 11, no. 4 (August 2002): 659–68. https://doi.org/10.1089/15258160260194802.
Morse, Michael A., and H Kim Lyerly. “DNA and RNA modified dendritic cell vaccines.” World J Surg 26, no. 7 (July 2002): 819–25. https://doi.org/10.1007/s00268-002-4058-0.
Clay, Timothy M., Michael Morse, and H Kim Lyerly. “Redirecting cytotoxic T lymphocyte responses with T-cell receptor transgenes.” Expert Opin Biol Ther 2, no. 4 (April 2002): 353–60. https://doi.org/10.1517/14712598.2.4.353.
Morse, Michael A., Timothy M. Clay, and H Kim Lyerly. “Current status of adoptive immunotherapy of malignancies.” Expert Opin Biol Ther 2, no. 3 (March 2002): 237–47. https://doi.org/10.1517/14712598.2.3.237.
Keilholz, Ulrich, Jeffrey Weber, James H. Finke, Dmitry I. Gabrilovich, W Martin Kast, Mary L. Disis, John M. Kirkwood, et al. “Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.” J Immunother 25, no. 2 (March 2002): 97–138. https://doi.org/10.1097/00002371-200203000-00001.
Morse, Michael A., Smita K. Nair, David Boczkowski, Douglas Tyler, Herbert I. Hurwitz, Alan Proia, Timothy M. Clay, Jeffrey Schlom, Eli Gilboa, and H Kim Lyerly. “The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer.” Int J Gastrointest Cancer 32, no. 1 (2002): 1–6. https://doi.org/10.1385/IJGC:32:1:1.
Morse, M. A., S. Nair, M. Fernandez-Casal, Y. Deng, M. St Peter, R. Williams, A. Hobeika, et al. “Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer.” J Clin Oncol 18, no. 23 (December 1, 2000): 3883–93. https://doi.org/10.1200/JCO.2000.18.23.3883.
Mosca, P. J., A. C. Hobeika, T. M. Clay, S. K. Nair, E. K. Thomas, M. A. Morse, and H. K. Lyerly. “A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment.” Blood 96, no. 10 (November 15, 2000): 3499–3504.
Li, Y., M. Bendandi, Y. Deng, C. Dunbar, N. Munshi, S. Jagannath, L. W. Kwak, and H. K. Lyerly. “Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells.” Blood 96, no. 8 (October 15, 2000): 2828–33.
Lyerly, H. K., T. Clay, and M. A. Morse. “Optimizing dendritic cell function by genetic modification.” J Natl Cancer Inst 92, no. 15 (August 2, 2000): 1198–99. https://doi.org/10.1093/jnci/92.15.1198.
Markert, M. L., C. B. Hicks, J. A. Bartlett, J. L. Harmon, L. P. Hale, M. L. Greenberg, G. Ferrari, et al. “Effect of highly active antiretroviral therapy and thymic transplantation on immunoreconstitution in HIV infection.” Aids Res Hum Retroviruses 16, no. 5 (March 20, 2000): 403–13. https://doi.org/10.1089/088922200309061.
Boczkowski, D., S. K. Nair, J. H. Nam, H. K. Lyerly, and E. Gilboa. “Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells.” Cancer Res 60, no. 4 (February 15, 2000): 1028–34.